Co-Diagnostic to Release FY2025 Q2 Earnings on August 14 After-Market EST, Forecast Revenue USD 300K, EPS USD -0.25

Brief Summary

Co-Diagnostic is expected to report Q2 2025 revenue of $30,000 and an EPS of -$0.25, which is generally below market expectations when compared to peers like AMD and Palantir, who reported significantly higher revenues and growth rates.

Impact of The News

Analysis of Co-Diagnostic’s Financial Results

• Revenue Expectation: Co-Diagnostic is predicted to report revenue of $30,000 for Q2 2025.
• Earnings Per Share (EPS): The anticipated EPS is -$0.25, indicating a loss.

Comparison with Peers

• AMD’s Performance: AMD reported Q2 2025 revenue of $7.69 billion, showing a 31.7% year-over-year growth and surpassing market expectations of $7.43 billion, with a strong performance in server and PC processor sales.
• Palantir’s Performance: Palantir achieved over $1 billion in revenue for Q2 2025 and saw a 140% year-over-year increase in order volume, with significant growth in U.S. commercial and government sectors.

Potential Impact and Implications

• Market Position: Co-Diagnostic’s expected revenue and EPS place it in a challenging position compared to its peers like AMD and Palantir, which have shown robust growth and exceeded expectations.
• Business Status: The negative EPS and low revenue suggest that Co-Diagnostic may be facing operational or strategic challenges that need addressing to compete effectively in the sector.
• Future Trends: If the company continues on this trajectory, there may be a need for strategic pivots or new initiatives to drive revenue growth and improve profitability. Investors may need to closely monitor management’s guidance and any strategic changes following the earnings report.